Day: March 17, 2022

Reports Record Annual Sales and Profit;Full-Year Sales of $505 Million, Net Income of $56.7 million, $0.83 EPS,Adjusted EBITDA of $76.9 millionAnnounces $15.0 Million Stock Repurchase Program CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest omni-channel specialty retailer of big and tall men’s apparel, today reported financial results for the fourth quarter and fiscal year 2021. Fourth Quarter HighlightsTotal sales for the fourth quarter were $133.5 million, up 33.3% from $100.1 million for fiscal 2020 and up 1.7% from $131.2 million for fiscal 2019. Comparable sales increased 41.5% as compared to fiscal 2020 and 9.4% as compared to fiscal 2019. Net income for the fourth quarter was $9.9 million, or $0.14 per diluted share, as compared to a net loss of $(5.1) million, or...

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 – – Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2 2022 – – $136.6 million in cash, cash equivalents and marketable securities support projected runway into 2024 – – Conference call and webcast at 8:30 a.m. ET today – CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2021 and provided an update on pipeline programs. “2021 was a transformational year for Synlogic highlighted by proof of concept...

Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conference Call Begins Today at 8:30 am ET YAVNE, Israel, March 17, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. Fourth Quarter, Full-Year 2021 and Recent Weeks Financial Highlights:Total revenues for 2021 were $23.8 million; compared to $21.8 million in 2020   Product revenues in 2021 increased by...

Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead targeted oncology program, into the clinic, continuing leadership in the Hippo pathway therapeutic landscape Expanded IK-175 clinical trial cohorts for urothelial carcinoma patients enriched for nuclear AHR positivity; Second trial indication announced in head & neck squamous cell carcinoma Initiated multiple new discovery programs in the RAS & Hippo pathways Clinical data updates across the immune-signaling pipeline planned for second half 2022 BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full...

-FYARRO™ approved November 22, 2021 and launched February 23, 2022- –FYARRO added to NCCN® Guidelines as the only preferred therapy to treat malignant PEComa- -PRECISION 1 tumor agnostic study for TSC1 or TSC2 alterations open for enrollment- –Ended fourth quarter 2021 with $149.0 million in cash and cash equivalents- LOS ANGELES, March 17, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. “We are well-positioned in 2022 with a strong team, a solid balance sheet, and a highly promising recently approved drug,” stated...

FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launchExpanded the robust portfolio of data supporting the potential impact of FT218 on people living with narcolepsy with multiple presentations at World Sleep 2022Appointed Dr. Douglas Williamson as Chief Medical Officer and Brandi Robinson as Senior Vice President, Corporate AffairsExtended the maturity on $117.4 million of convertible notes to October 2, 2023Management to host a conference call today at 8:30 a.m. ETDUBLIN, Ireland, March 17, 2022 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2021. “Avadel...

– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4 and 28-day safety data for cohort A5 expected at upcoming scientific meetings in mid-2022 – – MuSK-CAART Investigational New Drug (IND) application cleared and Fast Track Designation granted by the U.S. Food and Drug Administration (FDA); planning to initiate first-in-human trial in 2022 – – Ended 2021 with $122.2 million in cash on hand to fund operations through 3Q 2023 – PHILADELPHIA, March 17, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided...

SHENZHEN, China, March 17, 2022 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading innovator in shared cloud computing and blockchain technology in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights:Total revenues were US$71.1 million, representing an increase of 18.6% from the previous quarter.Cloud computing and other internet value-added services (“Cloud computing and other IVAS”) revenues were US$44.7 million, representing an increase of 26.9% from the previous quarter.Subscription revenues were US$23.7 million, representing an increase of 4.3% from the previous quarter.Online advertising revenues, consisting primarily of revenues from mobile advertising, were US$2.8 million,...

CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022 CLN-049 and CLN-619 patient dosing initiated in December 2021 for first-in-human clinical trials; initial clinical data expected by mid-2023 Portfolio advancement and expansion highlighted through multiple AACR abstract acceptances and HPK1 protein degrader collaboration with Mount Sinai CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today reported on recent and upcoming business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2021. “Cullinan Oncology is dedicated to developing new standards of care...